drugset / Trial / NCT02681094
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately controlled on ≥1500mg/day of metformin monotherapy.
Timeline
- Start
- 2016-02-26
- Primary completion
- 2017-07-15
- Completion
- 2017-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 5 mg | Oral |
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | 5 mg | Oral |